Productivity improvements in hepatitis C treatment: Impact on efficacy, cost, cost-effectiveness and quality of life

Scandinavian Journal of Gastroenterology

Volumn 42, Issue 7, 2007, Pages 867-877

  Lidgren, Mathias ^a,b   Hollander, Anna ^c   Weiland, Ola ^c   Jönsson, Bengt ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cost effectiveness; Cost utility; Hepatitis C; Individualized therapy; QALY

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; FOLLOW UP; GENOTYPE; HEALTH CARE COST; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SWEDEN;

EID: 34250214151     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520601127208     Document Type: Article

References (46)

1. WHO Fact sheet No. 164. Revised October 2000; 2000.
2. National Institute of Health Consensus Statement. Management of Hepatitis C 1997;15:1-41.
3. Socialstyrelsen. Yearbook of health and medical care 2002. Stockholm: Socialstyrelsen; 2003.
4. Kobelt G. Health economics: an introduction to economic evaluations, 2nd ed. London: Office of Health Economics; 2002.
5. Hollander A, Foster G, Weiland O. Health related quality of life prior to, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C. Scand J Gastroenterol 2006;41:577-85.
6. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996;23:1334-40.
7. Yano M, Yatsuhashi H, Inoue O, Inokuchi K, Koga M. Epidemiology and long term prognosis of hepatitis C virus infection in Japan. Gut 1993;34(Suppl 2):S13-6.
8. Yatsuhashi H, Yano M. Natural history of chronic hepatitis C. J Gastroenterol Hepatol 2000;15 Suppl:E111-6.
9. Statistics Sweden. Statistical yearbook of Sweden 2004. Vol 90. Statistics Sweden; 2003.
10. Lundberg L, Johannesson M, Isacson D, Borgquist L. Health-state utilities in a general population in relation to age, gender and socioeconomic factors. Eur J Public Health 1999;9:211-7.
11. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-32.
12. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-72.
13. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92.
14. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
15. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
16. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004;40:993-9.
17. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
18. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
19. Weiland O, Hollander A, Frisell K, Sandell S. Cost-effective therapy for genotype 2 and 3 chronic hepatitis C. Hepatology 2003;38(Suppl 1):739A.
20. Dalgard O, Bjoro K, Hellum KB, Myrvang B, Ritland S, Skaug K, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004;40:1260-5.
21. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609-17.
22. von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005;129:522-7.
23. Zeuzem S, Buti-ferrer M, Ferenci P, Sperl P, Horsmans Y, Ibranyi E, et al. Efficacy of 24 weeks treatment with peg_IFN alfa-2b plus ribavirin in patients with chronic hepatitis C infection with genotype 1 and low pre-treatment viremia. J Hepatol 2006;44:97-103.
24. Berg T, Wagner M, Hinrichsen H, Heintges T, Buggisch P, Goeser T, et al. Reduction of relative relapse rates by prolongation of the duration of therapy with peginterferon-alfa-2a plus ribavirin up to 72 weeks in patients with HCV type 1 infection. Gastroenterology 2006;130:1086-97.
25. National Medicine Information System. http://www.fass.se
26. Sennfalt K, Reichard O, Hultkrantz R, Wong JB, Jonsson D. Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden. Scand J Gastroenterol 2001;36:870-6.
27. McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994;32:40-66.
28. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247-63.
29. Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 1999;29:264-70.
30. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998;27:209-12.
31. Ware JE Jr, Bayliss MS, Mannocchia M, Davis GL. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology 1999;30:550-5.
32. Lundberg L, Johannesson M, Isacson DG, Borgquist L. The relationship between health-state utilities and the SF-12 in a general population. Med Decision-Making 1999;19:128-40.
33. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997;127:855-65.
34. Kim WR, Poterucha JJ, Hermans JE, Therneau TM, Dickson ER, Evans RW, et al. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med 1997;127:866-74.
35. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003;290:228-37.
36. Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, et al. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003;52:425-32.
37. Sullivan SD, Craxi A, Alberti A, Giuliani G, De Carli C, Wintfeld N, et al. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. Pharmacoeconomics 2004;22:257-65.
38. Wong JB, Bennett WG, Koff RS, Pauker SG. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. JAMA 1998;280:2088-93.
39. Wong JB, Davis GL, McHutchison JG, Manns MP, Albrecht JK. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol 2003;98:2354-62.
40. Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999;30:1318-24.
41. Gines P, Quintero E, Arroyo V, Teres J, Bruguera M, Rimola A, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987;7:122-8.
42. Colombo M, de Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tommasini M, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991;325:675-80.
43. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328:1797-801.
44. Ascher NL, Lake JR, Emond J, Roberts J. Liver transplantation for hepatitis C virus-related cirrhosis. Hepatology 1994;20:24S-7S.
45. Detre K, Belle S, Lombardero M. Liver transplantation for chronic viral hepatitis. Viral Hepatitis Rev 1996;2:219-28.
46. Kilpe VE, Krakauer H, Wren RE. An analysis of liver transplant experience from 37 transplant centers as reported to Medicare. Transplantation 1993;56:554-61.